Objective: To evaluate the growth and neurodevelopment outcomes of very low-birth-weight (VLBW) preterm infants supplemented with oral probiotics for the prevention of necrotizing enterocolitis (NEC).
Study Design: This prospective follow-up study was conducted in a cohort of VLBW preterm infants enrolled in a randomized controlled clinical trial to evaluate the efficacy of oral probiotics for the prevention of NEC. Growth outcomes included weight, length, and head circumference. Cognitive and neuromotor development were assessed by using the Bayley Scales of Infant Development II. Sensory and neurological performance was evaluated by standard techniques. The primary outcome was neurodevelopmental impairment at 18 to 22 months' corrected age.
Results: A total of 221 infants completed the trial protocol. Of the 208 infants eligible for follow-up, 174 infants (86 in the probiotics group and 88 in the control group) were evaluated. There was no significant difference in growth and neurodevelopmental outcomes between the two groups.
Conclusion: Oral probiotic administered to VLBW infants to reduce the incidence and severity of NEC started with the first feed did not affect growth, neuromotor, neurosensory, and cognitive outcomes at 18 to 22 months' corrected age.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0032-1311981 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Influence of Oral and Gut Microbiota on Ulcerative Mucositis: A Pilot Cohort Study.
Oral Dis
January 2025
Department for Conservative Dentistry, School of Dental Medicine, University Heidelberg, Heidelberg, Germany.
Aim: Comparing oral and gut microbiome profiles between patients with and without ulcerative mucositis during allogeneic stem cell transplantation (aSCT).
Materials And Methods: Specimens from oral mucosa, saliva, and stool were collected pre-(T0) and post- (T0 +28d ± 14d) aSCT (T1). Microbiome structure differences were analyzed by 16S-rRNA-gene sequencing, and associations to patients' clinical characteristics were investigated.
Dihydromyricetin/montmorillonite intercalation compounds ameliorates DSS-induced colitis: Role of intestinal epithelial barrier, NLRP3 inflammasome pathway and gut microbiota.
Int J Pharm
December 2024
Department of Gastroenterology, Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China; Key Laboratory of Digestive Diseases, Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Electronic address:
Dihydromyricetin (DHM), the primary active compound in vine tea possesses various pharmacological effects such as anti-inflammatory and antioxidant properties, along with high biosafety. However, its oral delivery remains a significant challenge. Montmorillonite (MMT), the primary component of bentonite, is a commonly used drug in the clinical treatment of gastrointestinal diseases and serves as an excellent drug carrier due to its intercalation capability.
View Article and Find Full Text PDFPreliminary report: Protective effects of probiotics on cefovecin-induced gut dysbiosis in dogs.
Can J Vet Res
January 2025
Laboratory of Veterinary Dermatology (Han, Hwang) and Research Institute for Veterinary Science (Han, Mun, Hwang), College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea; ORIGIN Veterinary Dermatology Clinic, Busan, Republic of Korea (Kang); Department of Companion Animal Health Care, College of Medical Health, Kyungbok University, Namyangju, Republic of Korea (Kim S-J); Department of Large Animal Internal Medicine, College of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of Korea (Kim Y-H).
The objective of this study was to evaluate whether supplementation with probiotics over a 2-week period stabilizes the gut microbiota in dogs following prolonged cefovecin treatment. A significant number of clinical veterinarians prescribe oral probiotics to dogs in conjunction with systemic antibiotics with the intention of protecting against gut dysbiosis. The effects of antibiotics and probiotics in dogs have not been extensively studied, however, and the optimal treatment for gut dysbiosis remains uncertain.
View Article and Find Full Text PDFE. coli Nissle 1917 improves gut microbiota composition and serum metabolites to counteract atherosclerosis via the homocitrulline/Caspase 1/NLRP3/GSDMD axis.
Int J Med Microbiol
December 2024
Insititute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, University of South China, Hengyang, Hunan 421001, China. Electronic address:
Article Synopsis
- The probiotic E. coli Nissle 1917 (EcN) was studied for its effects on atherosclerosis in mice fed a high-fat diet, revealing its potential to alleviate disease progression.
- EcN treatment reduced atherosclerotic plaque formation, improved cholesterol levels, and inhibited the expression of pyroptosis-related proteins linked to inflammation.
- Further analysis showed that EcN regulated gut microbiota and metabolite levels, suggesting a mechanism for its beneficial effects, although antibiotics partially reversed these outcomes.
Gut Commensal Barnesiella Intestinihominis Ameliorates Hyperglycemia and Liver Metabolic Disorders.
Adv Sci (Weinh)
December 2024
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China.
Recent studies have highlighted the role of the gut microbiota in type 2 diabetes (T2D). Improving gut microbiota dysbiosis can be a potential strategy for the prevention and management of T2D. Here, this work finds that the abundance of Barnesiella intestinihominis is significantly decreased in the fecal of T2D patients from 2-independent centers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!